In a stunning turn of events, Bristol-Myers Squibb $BMY has struck a deal to buy Celgene $CELG for $74 billion in cash and stock. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
